TheraRadar
Landscape / CNS
Data updated: Jun 28, 2026

Huntington's Disease Clinical Trial Landscape

Huntington's Disease is being studied across 106 clinical trials registered since 2008, with 22 programs currently active. The competitive pipeline includes 6 active Phase 3 trials, 12 active Phase 2 trials, and 4 active Phase 1 trials.

Top industry sponsors include Roche, Skyhawk Therapeutics, Inc., Novartis.

Trial activity

22 active / 106 total since 2008
Active by phase 6 Ph3 / 18 12 Ph2 / 54 4 Ph1 / 32 0 Ph4 / 2

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Roche 3 3 0
Skyhawk Therapeutics, Inc. 3 0 0
Novartis 2 1 2
UniQure Biopharma B.V. 2 0 0
Prilenia 1 4 1
Luye Pharma Group Ltd. 1 3 0
Alnylam Pharmaceuticals 1 0 0
Sarepta Therapeutics, Inc. 1 0 0
ExoRNA Bioscience 1 0 0
AskBio France, SAS, a subsidiary of AskBio Inc. 1 0 0
Vico Therapeutics B. V. 1 0 0
Pfizer 0 11 1
Wave Life Sciences Ltd. 0 1 4
Supernus Pharmaceuticals, Inc. 0 3 1
Siena Biotech S.p.A. 0 4 0

All 15 active Huntington's Disease sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2022 (8 registered); 2025 saw 5. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (11 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
2
2017
5
2018
3
2019
6
2020
4
2021
5
2022
8
2023
5
2024
5
2025
5
2026
7

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (0)
0
2017 (0)
0
2018 (0)
0
2019 (2)
128
2020 (1)
499
2021 (1)
30
2022 (2)
107
2023 (0)
0
2024 (0)
0
2025 (1)
120
2026 (4)
450

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT07326709 RECRUITING
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals n=770
NCT06873334 ACTIVE NOT RECRUITING
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=120
NCT07537075 ENROLLING BY INVITATION
An Extension of SKY-0515 in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=500
NCT07378644 RECRUITING
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=400
NCT04713982 ACTIVE NOT RECRUITING
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Vanderbilt University Medical Center n=30
NCT07609108 NOT YET RECRUITING
Pridopidine Phase 3 Study in Huntington's Disease
Prilenia n=400
NCT05655520 TERMINATED
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Supernus Pharmaceuticals, Inc. n=153
NCT04826692 COMPLETED
TEsting METformin Against Cognitive Decline in HD
Instituto de Investigacion Sanitaria La Fe n=60
NCT04556656 COMPLETED
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Prilenia n=499
NCT03854019 COMPLETED
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
The University of Texas Health Science Center, Houston n=20
NCT03842969 COMPLETED
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
Hoffmann-La Roche n=236
NCT00665223 COMPLETED
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
Teva Branded Pharmaceutical Products R&D, Inc. n=437
NCT01897896 COMPLETED
Alternatives for Reducing Chorea in Huntington Disease
Auspex Pharmaceuticals, Inc. n=119
NCT00632645 COMPLETED
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Assistance Publique - Hôpitaux de Paris n=180
NCT01085266 TERMINATED
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
Medivation, Inc. n=362
NCT00920946 COMPLETED
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Medivation, Inc. n=403
NCT00608881 TERMINATED
Coenzyme Q10 in Huntington's Disease (HD)
Massachusetts General Hospital n=609
NCT00712426 TERMINATED
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Massachusetts General Hospital n=553

Full Huntington's Disease Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only